Collplant Biotechnologies Ltd NASDAQ NMS - GLOBAL MARKET:CLGN
The leadership team, board of directors, and 10% beneficial owners of Collplant Biotechnologies Ltd, reconstructed from SEC insider filings and proxy statements.
Other Reporting Persons
Other Section-16 reporting persons associated with the issuer.
Abelis Bar Berta
—40,000 sharesBagley Bowman
—25,000 sharesBensimon Philippe
—2,000 sharesFahimipoor Oren
—30,000 sharesHavron Avraham
—10,000 sharesLask Alisa
—10,000 sharesPenn Elan
—7,500 sharesRotem Eran
—60,000 sharesSeror Jasmine
—45,000 sharesTal Yehiel
—31,137 shares
Recent Form 4 Activity last 90 days
No insider transactions in the last 90 days.
View all insider tradesMethodology
Officers and directors are derived from SEC Forms 3, 4, and 5 filed by reporting persons for this issuer. The roster reflects the most recent disclosed relationship per individual. Officer titles use the issuer-supplied designation from the relationship record.
Independence flags and board committee assignments are sourced from the most recent DEF 14A proxy statement when available. For executive compensation context — base salary, equity grants, performance metrics — refer to the Summary Compensation Table in the issuer's annual proxy.
Cross-references: where a reporting person is matched to a consolidated people profile (same CIK across multiple issuers), the person link routes to the unified profile page so you can see every board seat and officer role in one place.